Abstract: The present disclosure provides methods for treating or inhibiting the growth of MET associated non-small cell lung cancer comprising selecting a subject with cancer and administering a therapeutically effective amount of a MET x MET bispecific antibody where each binding arm of the bispecific antibody interacts with a different MET epitope. In certain embodiments, the cancer harbors a MET alteration such as an exon 14 alteration in DNA or a deletion that leads to exon 14 skipping, a MET gene amplification, or MET protein overexpression.